|Tested species reactivity||Human, Non-human primate, Rat|
|Published species reactivity||Rat|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Purified recombinant fragment of human AURKA expressed in E. Coli.|
|Contains||0.03% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1/200 - 1/400|
|Immunofluorescence (IF)||1/200 - 1/1000|
|Western Blot (WB)||1/500 - 1/2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 1 publications below|
MA5-15803 targets AURKA in FACS, IF, and WB applications and shows reactivity with Human, Non-human primate, and Rat samples.
The MA5-15803 immunogen is purified recombinant fragment of human AURKA expressed in E. Coli.
MA5-15803 detects AURKA which has a predicted molecular weight of approximately 48kDa.
Aurora A plays a role in cell cycle regulation during anaphase and/or telophase, in relation to the function of the centrosome/spindle pole region during chromosome segregation. Aurora A plays a key role during tumor development and progression and is overexpressed in many human cancers including breast, ovarian and colorectal. Aurora A is viewed as a potential target for anticancer drug treatment.Tissue specificity: Highly expressed in testis and weakly in skeletal muscle, thymus and spleen. Also highly expressed in colon, ovarian, prostate, neuroblastoma, breast and cervical cancer cell lines.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Inhibitory effect of caffeic acid phenethyl ester on the growth of C6 glioma cells in vitro and in vivo.
MA5-15803 was used in western blot to study the inhibition of C6 glioma cell growth by caffeic acid phenethyl ester and the potential mechanisms involved
|Kuo HC,Kuo WH,Lee YJ,Lin WL,Chou FP,Tseng TH||Cancer letters (234:199)||2006|